TruNorth Capital Management LLC Increases Position in Stryker Corporation $SYK

TruNorth Capital Management LLC lifted its position in shares of Stryker Corporation (NYSE:SYK) by 2.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 22,146 shares of the medical technology company’s stock after buying an additional 445 shares during the period. Stryker accounts for approximately 1.9% of TruNorth Capital Management LLC’s portfolio, making the stock its 11th largest holding. TruNorth Capital Management LLC’s holdings in Stryker were worth $8,762,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. jvl associates llc lifted its stake in shares of Stryker by 14.9% during the second quarter. jvl associates llc now owns 756 shares of the medical technology company’s stock valued at $299,000 after buying an additional 98 shares during the period. First Pacific Financial increased its position in Stryker by 572.9% during the second quarter. First Pacific Financial now owns 323 shares of the medical technology company’s stock worth $128,000 after purchasing an additional 275 shares during the last quarter. Deltec Asset Management LLC increased its position in Stryker by 35.2% during the second quarter. Deltec Asset Management LLC now owns 2,690 shares of the medical technology company’s stock worth $1,064,000 after purchasing an additional 700 shares during the last quarter. QTR Family Wealth LLC increased its position in Stryker by 7.4% during the second quarter. QTR Family Wealth LLC now owns 801 shares of the medical technology company’s stock worth $317,000 after purchasing an additional 55 shares during the last quarter. Finally, Trust Co. of Vermont increased its position in Stryker by 2.4% during the second quarter. Trust Co. of Vermont now owns 32,393 shares of the medical technology company’s stock worth $12,816,000 after purchasing an additional 750 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

SYK has been the subject of several research analyst reports. Evercore ISI upped their price target on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Rothschild & Co Redburn initiated coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target for the company. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Fourteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $430.33.

Stryker Price Performance

Stryker stock opened at $364.07 on Thursday. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The firm has a fifty day moving average of $384.08 and a 200-day moving average of $379.01. The firm has a market capitalization of $139.19 billion, a P/E ratio of 48.22, a PEG ratio of 2.66 and a beta of 0.95. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s revenue was up 11.1% on a year-over-year basis. During the same period last year, the business earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.